Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical TrialThe shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization from Health Canada and import authorization from the UK Home Office
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product DevelopmentRecent US executive order named ibogaine compounds among the psychedelic therapies prioritized for accelerated FDA review and expanded patient access
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in AustraliaOptimi’s 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional product from the run earmarked for planned clinical trials in the United States and Europe
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in AustraliaUpdated TGA recommendations broaden therapist eligibility, accept a wider range of treatment settings, and reinforce Australia's position as the world's leading commercial market for prescribed psilocybin and MDMA
Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting(May 20, 2026) - Optimi Health Corp. (
NASDAQ:OPTH) (CSE:OPTI) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and
